Drug Profile
Research programme: cytomegalovirus vaccines - Pfizer
Alternative Names: Cytomegalovirus reVLPs®; Cytomegalovirus VLPs - Redbiotec; RBT 301; RBT 302; RBT 303; RBT 304; RBT 305; RBT 306Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Redbiotec; Redvax
- Developer Pfizer
- Class Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cytomegalovirus infections